|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, December 10, 2016 ) Hyperoxaluria is defined by the presence of excess amounts of oxalic acid (oxalate) in the urine. Symptoms include severe or sudden abdominal or flank pain, blood in the urine, fever and chills, loss of appetite, nausea and vomiting. Treatment includes a low-oxalate diet and vitamin B-6.
Report Highlights
Publisher's Pharmaceutical and Healthcare latest pipeline guide Hyperoxaluria - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hyperoxaluria (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hyperoxaluria (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Hyperoxaluria and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 3, 1 and 1 respectively.Hyperoxaluria.
Hyperoxaluria (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
For more information about this report at http://www.reportsweb.com/hyperoxaluria-pipeline-review-h2-2016
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperoxaluria (Genito Urinary System And Sex Hormones).
- The pipeline guide reviews pipeline therapeutics for Hyperoxaluria (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hyperoxaluria (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hyperoxaluria (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hyperoxaluria (Genito Urinary System And Sex Hormones)
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001492642/sample
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hyperoxaluria (Genito Urinary System And Sex Hormones).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hyperoxaluria (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Companies profiles
Allena Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc
Dicerna Pharmaceuticals Inc
OxThera AB
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001492642/discount
List of Tables
Number of Products under Development for Hyperoxaluria, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Clinical Stage Development, H2 2016 9
Comparative Analysis by Early Stage Development, H2 2016 10
Products under Development by Companies, H2 2016 11
Hyperoxaluria - Pipeline by Allena Pharmaceuticals Inc, H2 2016 12
Hyperoxaluria - Pipeline by Alnylam Pharmaceuticals Inc, H2 2016 13
Hyperoxaluria - Pipeline by Dicerna Pharmaceuticals Inc, H2 2016 14
Hyperoxaluria - Pipeline by OxThera AB, H2 2016 15
Assessment by Monotherapy Products, H2 2016 16
List of Figures
Number of Products under Development for Hyperoxaluria, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Clinical Stage Development, H2 2016 9
Comparative Analysis by Early Stage Products, H2 2016 10
Assessment by Monotherapy Products, H2 2016 16
Number of Products by Routes of Administration, H2 2016 19
Number of Products by Stage and Routes of Administration, H2 2016 19
Number of Products by Molecule Types, H2 2016 21
Number of Products by Stage and Molecule Types, H2 2016 21
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
